PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come

ESMO Open. 2020 Aug;5(4):e000890. doi: 10.1136/esmoopen-2020-000890.

Author

Leticia De Mattos-Arruda^{1

2}

Affiliations

¹ IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain [email protected].
² Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.

No abstract available

Keywords: PIK3CA mutation; alpelisib; breast cancer; endocrine therapy resistance; hormonal receptor.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Breast Neoplasms* / genetics
Class I Phosphatidylinositol 3-Kinases
Female
Hormones
Humans
Phosphatidylinositol 3-Kinases
Receptor, ErbB-2

Substances

Hormones
Class I Phosphatidylinositol 3-Kinases
PIK3CA protein, human
Receptor, ErbB-2